Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer

Breast Cancer Research

Volumn 16, Issue 4, 2014, Pages

  Jovanović, Bojana ^a   Beeler, J S ^b   Pickup, Michael W ^a   Chytil, Anna ^a   Gorska, Agnieszka E ^a   Ashby, William J ^c   Lehmann, Brian D ^b   Zijlstra, Andries ^b   Pietenpol, Jennifer A ^a,b   Moses, Harold L ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Scibrary the Science Library   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; BONE MORPHOGENETIC PROTEIN 4; MESSENGER RNA; PROTEOGLYCAN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR PROMOTION; APOPTOSIS; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CELL VIABILITY; COMPARATIVE STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL MOTION; CELL SURVIVAL; CELL TRANSFORMATION; CLUSTER ANALYSIS; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; INTEGRIN ALPHA2; MESENCHYMAL STROMAL CELLS; MICE; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84904092530     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3684     Document Type: Article

References (53)

1. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014, 232:142-150.
2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
3. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003, 100:8621-8623.
4. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008, 68:1809-1819.
5. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520.
6. López-Casillas F, Payne HM, Andres JL, Massagué J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 1994, 124:557-568.
7. Blobe GC, Liu X, Fang SJ, How T, Lodish HF. A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 2001, 276:39608-39617.
8. Blobe GC. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem 2001, 276:24627-24637.
9. Lee JD, Hempel N, Lee NY, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis 2010, 31:175-183.
10. Wang XF, Lin HY, Ng-Eaton EE, Downward JJ, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-beta type III receptor. Cell 1991, 67:797-805.
11. Cheifetz S, Like B, Massague J. Cellular distribution of type I and type II receptors for transforming growth factor-beta. J Biol Chem 1986, 261:9972-9978.
12. Massague J. Transforming growth factor-beta modulates the high-affinity receptors for epidermal growth factor and transforming growth factor-alpha. J Cell Biol 1985, 100:1508-1514.
13. Massague J, Like B. Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 1985, 260:2636-2645.
14. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007, 67:1090-1098.
15. Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 2007, 67:5231-5238.
16. Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 2008, 29:252-262.
17. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood CG. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 2003, 22:8053-8062.
18. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 2007, 117:206-217.
19. Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res 2008, 68:7304-7312.
20. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 2009, 119:1571-1582.
21. Ashby WJ, Wikswo JP, Zijlstra A. Magnetically attachable stencils and the non-destructive analysis of the contribution made by the underlying matrix to cell migration. Biomaterials 2012, 33:8189-8203.
22. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
23. Kusanagi K, Inoue H, Ishidou Y, Mishima HK, Kawabata M, Miyazono K. Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol Biol Cell 2000, 11:555-565.
24. R Development Core Team R: A Language and Environment for Statistical Computing 2013, Vienna, Austria, R Development Core Team.
25. Wickham H. ggplot2: Elegant Graphics for Data Analysis 2009, New York: Springer.
26. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210.
27. Expression data from TGFBR3 controls and TGFBR3 knockdown SUM159 3D cultures. [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54756].
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
29. Andres JL, Ronnstrand L, Cheifetz S, Massague J. Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan. J Biol Chem 1991, 266:23282-23287.
30. Andres JL, Stanley K, Cheifetz S, Massagué J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol 1989, 109:3137-3145.
31. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
32. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 1991, 67:785-795.
33. Shimanuki T, Hara T, Furuya T, Imamura T, Miyazono K. Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling. Oncogene 2007, 26:3311-3320.
34. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 1991, 266:23048-23052.
35. Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 2008, 283:7628-7637.
36. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM. The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011, 121:226-237.
37. Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC. Type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest 2013, 123:4786-4798.
38. Liu J, Kuulasmaa T, Kosma VM, Butzow R, Vanttinen T, Hyden-Granskog C, Voutilainen R. Expression of betaglycan, an inhibin coreceptor, in normal human ovaries and ovarian sex cord-stromal tumors and its regulation in cultured human granulosa-luteal cells. J Clin Endocrinol Metab 2003, 88:5002-5008.
39. Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykala-Ciesla J, Wilczok T. Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Med Sci Monit 2004, 10:CR33-CR37.
40. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003, 1:346-361.
41. Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis 2008, 29:905-912.
42. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012, 13:616-630.
43. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009, 1792:954-973.
44. Andres JL, DeFalcis D, Noda M, Massague J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 1992, 267:5927-5930.
45. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993, 73:1435-1444.
46. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 2001, 276:14588-14596.
47. Zutter MM, Mazoujian G, Santoro SA. Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 1990, 137:863-870.
48. Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. TbetaRIII/beta-arrestin2 regulates integrin alpha5beta1 trafficking, function, and localization in epithelial cells. Oncogene 2013, 32:1416-1427.
49. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol 1996, 135:1633-1642.
50. Chen Q, Lin TH, Der CJ, Juliano RL. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. J Biol Chem 1996, 271:18122-18127.
51. Renshaw MW, Price LS, Schwartz MA. Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. J Cell Biol 1999, 147:611-618.
52. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004, 117:4619-4628.
53. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A. Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001, 276:23341-23348.